S&P 500   4,568.86 (+0.04%)
DOW   36,146.01 (+0.06%)
QQQ   386.48 (-0.21%)
AAPL   192.52 (-0.47%)
MSFT   368.94 (-0.96%)
META   318.91 (+0.19%)
GOOGL   130.51 (-0.37%)
AMZN   145.08 (-1.23%)
TSLA   243.35 (+1.94%)
NVDA   462.86 (-0.60%)
NIO   8.15 (+9.69%)
BABA   72.23 (-0.21%)
AMD   119.31 (+0.79%)
T   17.03 (-1.10%)
F   10.80 (+1.89%)
MU   73.73 (+0.05%)
CGC   0.70 (+5.07%)
GE   120.41 (+0.15%)
DIS   92.06 (+1.40%)
AMC   6.91 (-1.57%)
PFE   29.27 (+0.62%)
PYPL   59.80 (+3.25%)
XOM   99.18 (-1.25%)
S&P 500   4,568.86 (+0.04%)
DOW   36,146.01 (+0.06%)
QQQ   386.48 (-0.21%)
AAPL   192.52 (-0.47%)
MSFT   368.94 (-0.96%)
META   318.91 (+0.19%)
GOOGL   130.51 (-0.37%)
AMZN   145.08 (-1.23%)
TSLA   243.35 (+1.94%)
NVDA   462.86 (-0.60%)
NIO   8.15 (+9.69%)
BABA   72.23 (-0.21%)
AMD   119.31 (+0.79%)
T   17.03 (-1.10%)
F   10.80 (+1.89%)
MU   73.73 (+0.05%)
CGC   0.70 (+5.07%)
GE   120.41 (+0.15%)
DIS   92.06 (+1.40%)
AMC   6.91 (-1.57%)
PFE   29.27 (+0.62%)
PYPL   59.80 (+3.25%)
XOM   99.18 (-1.25%)
S&P 500   4,568.86 (+0.04%)
DOW   36,146.01 (+0.06%)
QQQ   386.48 (-0.21%)
AAPL   192.52 (-0.47%)
MSFT   368.94 (-0.96%)
META   318.91 (+0.19%)
GOOGL   130.51 (-0.37%)
AMZN   145.08 (-1.23%)
TSLA   243.35 (+1.94%)
NVDA   462.86 (-0.60%)
NIO   8.15 (+9.69%)
BABA   72.23 (-0.21%)
AMD   119.31 (+0.79%)
T   17.03 (-1.10%)
F   10.80 (+1.89%)
MU   73.73 (+0.05%)
CGC   0.70 (+5.07%)
GE   120.41 (+0.15%)
DIS   92.06 (+1.40%)
AMC   6.91 (-1.57%)
PFE   29.27 (+0.62%)
PYPL   59.80 (+3.25%)
XOM   99.18 (-1.25%)
S&P 500   4,568.86 (+0.04%)
DOW   36,146.01 (+0.06%)
QQQ   386.48 (-0.21%)
AAPL   192.52 (-0.47%)
MSFT   368.94 (-0.96%)
META   318.91 (+0.19%)
GOOGL   130.51 (-0.37%)
AMZN   145.08 (-1.23%)
TSLA   243.35 (+1.94%)
NVDA   462.86 (-0.60%)
NIO   8.15 (+9.69%)
BABA   72.23 (-0.21%)
AMD   119.31 (+0.79%)
T   17.03 (-1.10%)
F   10.80 (+1.89%)
MU   73.73 (+0.05%)
CGC   0.70 (+5.07%)
GE   120.41 (+0.15%)
DIS   92.06 (+1.40%)
AMC   6.91 (-1.57%)
PFE   29.27 (+0.62%)
PYPL   59.80 (+3.25%)
XOM   99.18 (-1.25%)

Fusion Antibodies Share Price, News & Analysis (LON:FAB)

GBX 4.68
-0.20 (-4.00%)
(As of 04:27 PM ET)
Compare
Today's Range
4.50
5.50
50-Day Range
3.30
7.33
52-Week Range
3.02
70
Volume
1.37 million shs
Average Volume
970,896 shs
Market Capitalization
£2.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

FAB stock logo

About Fusion Antibodies Stock (LON:FAB)

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. It serves pharmaceutical, biotech, and diagnostic companies. The company has a collaboration partnership with Celonic AG. The company was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.

FAB Stock Price History

FAB Stock News Headlines

Henry Ford Would NEVER Have Seen This Coming
In 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.
Henry Ford Would NEVER Have Seen This Coming
In 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.
Antibody Engineering Services Market Growth by 2031
See More Headlines
Receive FAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fusion Antibodies and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
48
Year Founded
N/A

Profitability

Net Income
£-2,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£2.90 million
Cash Flow
GBX 0.52 per share
Book Value
GBX 4 per share

Miscellaneous

Free Float
N/A
Market Cap
£2.78 million
Optionable
Not Optionable
Beta
0.56
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Adrian Robert Kinkaid Ph.D. (Age 56)
    CEO & Director
    Comp: $183.49k
  • Dr. Richard John Buick Ph.D. (Age 47)
    Chief Scientific Officer & Director
    Comp: $127k
  • Prof. Jim Johnston
    Founder
  • Mr. Stephen Barry Smyth (Age 48)
    Company Secretary, Interim CFO & Director
  • Ms. Nicola Hamilton
    Operations Manager
  • Dr. Paul Gerard Kerr (Age 50)
    Consultant
    Comp: $180.38k














FAB Stock Analysis - Frequently Asked Questions

How have FAB shares performed in 2023?

Fusion Antibodies' stock was trading at GBX 45 at the beginning of 2023. Since then, FAB stock has decreased by 89.3% and is now trading at GBX 4.80.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Fusion Antibodies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Antibodies investors own include D4t4 Solutions (D4T4), Aminex (AEX), Eurasia Mining (EUA), Dril-Quip (DRQ), 4D pharma (DDDD), ABM Industries (ABM), Card Factory (CARD), Blockchain Worldwide (BLOC), ATTRAQT Group (ATQT) and

How do I buy shares of Fusion Antibodies?

Shares of FAB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:FAB) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -